SCHEMBL3711268

SCHEMBL3711268

NC(=O)c1nsc(-c2ccccc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.55
ADORA2A P29274 1/20 0.55
ADORA2B P29275 1/20 0.55
ADORA1 P30542 1/20 0.55
KDM4E B2RXH2 2/20 0.46
TP53 P04637 2/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
CDC7 O00311 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8947158 0.85 ADORA3 (0.53) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL7656935 0.75 KDM4E (0.63) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL11643375 0.74 TRPM8 (0.57) ADORA3KDM4ETP53HSD17B10NPC1
SCHEMBL6581811 0.71 ADORA3 (0.59) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL8101030 0.71 ADORA3 (0.59) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL1135524 0.71 ADORA2A (1.00) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL8340158 0.70 ADORA3 (0.54) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL2212694 0.69 CYP19A1 (0.67) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL6501260 0.68 MEN1 (0.66) ADORA3ADORA2AADORA2BADORA1KDM4E
SCHEMBL3266075 0.68 TP53 (0.56) ADORA3ADORA2AADORA2BADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398771-A2 HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2011-12-28 EP claimed
WO-2010096371-A2 HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-26 WO claimed
US-8889670-B2 Heterocyclic compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 US disclosed
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ADORA3 198/4885ADORA2A 92/4885ADORA2B 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.